Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Jan 19, 2021 1:18pm
90 Views
Post# 32327365

RE:RE:RE:RE:RE:RE:RE:RE:RE:New investors from the deal

RE:RE:RE:RE:RE:RE:RE:RE:RE:New investors from the dealMy point is they need to bring in midium to long term investors on board who are convinced to stay put which CYDY has managed but not our company due to marketing issue , apart from last few days the daily volume is nothing compared to CYDY so yes the damping effect of millions of warrants hanging about on a illiquid equity  with a company who can't market will be much more than CYDY.
In a sense what you suggested convert the investors to traders which is the opposite scenario the company should aim for.
SPCEO1 wrote: You may have noticed the presence of warrants, literally hundred of millions of warrants, has not hindered CYDY from seeing its s tock advance ina stratospheric way.

More seriously, I am not sure that your concern, if I understand it correctly, is legitimate. The warrants are not goingt o control the share price. What is the difference if the company raises money via warrants converting or any other form of financing? We know this funding is only going to cover two years of trial expenses so we know they are going to be raising more money no matter what. So, I am not sure what your point is.

scarlet1967 wrote: The company is supposed to support the valuation as the SP is well undervalued, how would they be able to attract new institutional and retail investors when they are millions of warrant issued, who would even consider investing in the company when they know the SP will be controlled by warrant holders in the next few years?




<< Previous
Bullboard Posts
Next >>